Frederic J. Reu

4.4k total citations · 1 hit paper
58 papers, 2.1k citations indexed

About

Frederic J. Reu is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Frederic J. Reu has authored 58 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 40 papers in Hematology and 15 papers in Oncology. Recurrent topics in Frederic J. Reu's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (8 papers). Frederic J. Reu is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (8 papers). Frederic J. Reu collaborates with scholars based in United States, Canada and China. Frederic J. Reu's co-authors include Ernest C. Borden, Daniel J. Lindner, Songa Bae, Barbara Jacobs, Robert Z. Orlowski, Brian G.M. Durie, Stephen P. Kahanic, Muneer H. Abidi, Antje Hoering and Bart Barlogie and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Frederic J. Reu

54 papers receiving 2.0k citations

Hit Papers

Bortezomib with lenalidomide and dexamethasone versus len... 2016 2026 2019 2022 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
    2016 594 citations Brian G.M. Durie, Antje Hoering et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frederic J. Reu United States 19 1.6k 1.1k 748 246 215 58 2.1k
K C Anderson United States 16 1.5k 0.9× 1.1k 1.0× 794 1.1× 174 0.7× 197 0.9× 20 2.0k
Elisabet E. Manasanch United States 17 1.2k 0.7× 721 0.7× 717 1.0× 140 0.6× 126 0.6× 108 1.7k
Jian‐Qing Mi China 22 1.4k 0.9× 991 0.9× 379 0.5× 278 1.1× 337 1.6× 92 2.1k
Rui-Yu Wang United States 14 964 0.6× 472 0.4× 669 0.9× 336 1.4× 262 1.2× 20 1.7k
Claire Seedhouse United Kingdom 25 1.1k 0.7× 547 0.5× 548 0.7× 118 0.5× 246 1.1× 62 1.7k
Iris Breitkreutz United States 14 879 0.5× 1.0k 1.0× 697 0.9× 204 0.8× 101 0.5× 34 1.5k
Jake Shortt Australia 25 1.3k 0.8× 665 0.6× 756 1.0× 493 2.0× 172 0.8× 119 2.3k
K. Martin Kortüm Germany 25 1.0k 0.6× 941 0.9× 901 1.2× 240 1.0× 107 0.5× 103 1.8k
Sören Lehmann Sweden 27 1.2k 0.7× 1.2k 1.2× 667 0.9× 243 1.0× 353 1.6× 77 2.3k
Yawara Kawano Japan 17 742 0.5× 584 0.6× 406 0.5× 237 1.0× 216 1.0× 67 1.2k

Countries citing papers authored by Frederic J. Reu

Since Specialization
Citations

This map shows the geographic impact of Frederic J. Reu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederic J. Reu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederic J. Reu more than expected).

Fields of papers citing papers by Frederic J. Reu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederic J. Reu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederic J. Reu. The network helps show where Frederic J. Reu may publish in the future.

Co-authorship network of co-authors of Frederic J. Reu

This figure shows the co-authorship network connecting the top 25 collaborators of Frederic J. Reu. A scholar is included among the top collaborators of Frederic J. Reu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederic J. Reu. Frederic J. Reu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chandana, Sreenivasa R, Dale R. Shepard, Janice M. Mehnert, et al.. (2024). DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.. Journal of Clinical Oncology. 42(16_suppl). TPS11587–TPS11587. 1 indexed citations
2.
Tolcher, Anthony W., David S. Hong, Matthew L. Sherman, et al.. (2022). A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.. Journal of Clinical Oncology. 40(16_suppl). TPS3178–TPS3178. 8 indexed citations
3.
4.
Hu, Yi, Jianhong Lin, Fang Hua, et al.. (2018). Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 32(10). 2250–2262. 122 indexed citations
5.
Sidana, Surbhi, Mayur Narkhede, Paul Elson, et al.. (2017). Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE. 12(3). e0172996–e0172996. 18 indexed citations
6.
Vatolin, Sergei, James G. Phillips, Babal K. Jha, et al.. (2016). Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Research. 76(11). 3340–3350. 82 indexed citations
7.
Hong, Sanghee, Jason Valent, Lisa Rybicki, et al.. (2016). Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. Bone Marrow Transplantation. 51(5). 732–734. 2 indexed citations
8.
Luo, Hongmei, Yu Qin, Frederic J. Reu, et al.. (2016). Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. Journal of Hematology & Oncology. 9(1). 125–125. 17 indexed citations
9.
Durie, Brian G.M., Antje Hoering, Muneer H. Abidi, et al.. (2016). Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. The Lancet. 389(10068). 519–527. 594 indexed citations breakdown →
10.
Ebrahem, Quteba, Reda Z. Mahfouz, Lisa Durkin, et al.. (2015). Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response. Blood. 126(23). 678–678. 6 indexed citations
11.
Khan, Shahper N., A. Jankowska, Reda Z. Mahfouz, et al.. (2013). Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 27(6). 1301–1309. 104 indexed citations
12.
Vatolin, Sergei, Shahper N. Khan, & Frederic J. Reu. (2012). Direct Chromatin PCR (DC-PCR): Hypotonic Conditions Allow Differentiation of Chromatin States during Thermal Cycling. PLoS ONE. 7(9). e44690–e44690. 4 indexed citations
13.
Saunthararajah, Yogen, Pierre L. Triozzi, Brian I. Rini, et al.. (2012). p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. Seminars in Oncology. 39(1). 97–108. 39 indexed citations
14.
Lazaryan, Aleksandr, Brian J. Bolwell, Lisa Rybicki, et al.. (2012). The Role of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) in Autologous Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 18(2). S254–S254. 1 indexed citations
15.
Stewart, A. Keith, Andrzej Jakubowiak, Sundar Jagannath, et al.. (2011). The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study.. Journal of Clinical Oncology. 29(15_suppl). 8026–8026. 5 indexed citations
16.
Calabrese, Cassandra, Beth Faiman, David T. Martin, Frederic J. Reu, & Leonard H. Calabrese. (2011). Type 1 Cryoglobulinemia. JCR Journal of Clinical Rheumatology. 17(3). 145–147. 7 indexed citations
17.
Siegel, David S., Thomas G Martin, Ravi Vij, et al.. (2011). PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.. Journal of Clinical Oncology. 29(15_suppl). 8027–8027. 6 indexed citations
18.
Bae, Songa, Venugopalan Cheriyath, Barbara Jacobs, Frederic J. Reu, & Ernest C. Borden. (2007). Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene. 27(4). 490–498. 58 indexed citations
19.
Reu, Frederic J., et al.. (2007). Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Annals of Hematology. 86(10). 711–717. 21 indexed citations
20.
Chawla‐Sarkar, Mamta, Songa Bae, Frederic J. Reu, et al.. (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death and Differentiation. 11(8). 915–923. 306 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K C Anderson Breakdown of academic impact, for papers by Elisabet E. Manasanch Breakdown of academic impact, for papers by Jian‐Qing Mi Breakdown of academic impact, for papers by Rui-Yu Wang Breakdown of academic impact, for papers by Claire Seedhouse Breakdown of academic impact, for papers by Iris Breitkreutz Breakdown of academic impact, for papers by Jake Shortt Breakdown of academic impact, for papers by K. Martin Kortüm Breakdown of academic impact, for papers by Sören Lehmann Breakdown of academic impact, for papers by Yawara Kawano
Rankless by CCL
2026